Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

The Lancet

Volumn 373, Issue 9676, 2009, Pages 1673-1680

  Turpie, Alexander GG ^a   Lassen, Michael R ^b   Davidson, Bruce L ^c   Bauer, Kenneth A ^d   Gent, Michael ^a   Kwong, Louis M ^e   Cushner, Fred D ^f   Lotke, Paul A ^g   Berkowitz, Scott D ^h   Bandel, Tiemo J ^h   Benson, Alice ^h   Misselwitz, Frank ^h   Fisher, William D ⁱ  

^a MCMASTER UNIVERSITY   (Canada)

^b Hoersholm Hospital   (Denmark)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARBOR UCLA MEDICAL CENTER   (United States)

^f Insall Scott Kelly Institute   (United States)

^g HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^h BAYER PHARMA AG   (Germany)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; ENOXAPARIN; RIVAROXABAN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EMBOLISM PREVENTION; EPISTAXIS; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEART DEATH; HEART INFARCTION; HEMARTHROSIS; HEMATOMA; HEMATURIA; HEMOSTASIS; HUMAN; INTRASPINAL BLEEDING; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; THROMBOSIS PREVENTION; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING; VAGINA BLEEDING; VENOUS THROMBOEMBOLISM; VOMITING; WOUND CLOSURE; WOUND COMPLICATION; WOUND INFECTION;

EID: 65549169515     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60734-0     Document Type: Article

References (15)

1. Geerts W.H., Bergqvist D., Pineo G.F., et al., for the American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 (2008) 381S-453S
2. Caprini J.A., and Hyers T.M. Compliance with antithrombotic guidelines. Manag Care 15 (2006) 49-66
3. Eriksson B.I., Borris L.C., Friedman R.J., et al., for the RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358 (2008) 2765-2775
4. Lassen M.R., Ageno W., Borris L.C., et al., for the RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358 (2008) 2776-2786
5. Kakkar A.K., Brenner B., Dahl O.E., et al., for the RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372 (2008) 31-39
6. Rabinov K., and Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 104 (1972) 134-144
7. Colwell Jr. C.W., Berkowitz S.D., Davidson B.L., et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. J Thromb Haemost 1 (2003) 2119-2130
8. Ginsberg J.S., Davidson B.L., Comp P.C., et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24 (2009) 1-9
9. Lassen M., Gallus A., Pineo G., Raskob G., and for the ADVANCE-1 Investigators. Randomized double-blind comparison of apixaban with enoxaparin for thromboprophylaxis after knee replacement: the ADVANCE-1 trial. Blood (ASH Annual Meeting Abstracts) 112 (2008) 31
10. Colwell Jr. C.W., Berkowitz S.D., Lieberman J.R., et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 87 (2005) 2169-2177
11. Bauer K.A., Eriksson B.I., Lassen M.R., and Turpie A.G. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345 (2001) 1305-1310
12. Fuji T., Fujita S., Tachibana S., and Kawai Y. Randomized, double-blind, multi-dose efficacy, safety and biomarker study of the oral factor Xa inhibitor DU-176b compared with placebo for prevention of venous thromboembolism in patients after total knee arthroplasty. Blood (ASH Annual Meeting Abstracts) 112 (2008) 34
13. Strebel N., Prins M., Agnelli G., and Buller H.R. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?. Arch Intern Med 162 (2002) 1451-1456
14. Raskob G.E., and Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 124 (2003) 379S-385S
15. Cohen A.T., Hirst C., Sherrill B., Holmes P., and Fidan D. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. Br J Surg 92 (2005) 1335-1344